Company news
Faron Pharmaceuticals Oy (LSE:FARN) news
Faron Pharmaceuticals Oy news releases on 6ix. Latest, Oct 11, 2023: Faron Announces Positive BEXMAB Study Update
Press releases — page 5
Faron Announces Positive BEXMAB Study Update
October 11, 2023
Faron to host webcast on new BEXMAB study data
October 3, 2023
Results of EGM
September 22, 2023
Faron Appoints Interim Chief Medical Officer
September 21, 2023
Change in the Board of Directors
September 8, 2023
Faron to Present at H.C. Wainwright Conference
September 6, 2023
Notice of EGM
September 1, 2023
Faron 2023 Half-Year Financial Results
August 29, 2023
FDA Orphan Drug Designation for Bexmarilimab
August 29, 2023
Faron to Participate at Canaccord Conference
August 2, 2023
Grant of Options
July 25, 2023
Faron to Hold BEXMAB Study Conference Call
July 19, 2023
BEXMAB study update
July 19, 2023
New biomarker data from BEXMAB study at EHA2023
June 9, 2023
Board Member to Assume Transactional Advisor Role
June 5, 2023
Bexmarilimab Efficacy and Safety in MATINS Trial
April 24, 2023
Bexmarilimab KOL Event
April 19, 2023
Poster Presentations at AACR 2023
April 18, 2023
Faron at Canaccord Oncology Virtual Conference
April 13, 2023
Results of AGM
March 24, 2023
Positive FDA Feedback to Progress Bexmarilimab
March 22, 2023
Notice of Faron Pharmaceuticals Ltd's AGM
March 3, 2023
Faron´s Annual Report 2022 Published
March 3, 2023
Financial Statement January 1 to December 31 2022
March 3, 2023
Update to Faron's Financial Calendar for 2023
February 6, 2023
Notice of 2022 Full-Year Results and Annual Report
February 6, 2023
Price Monitoring Extension
January 16, 2023
Second Price Monitoring Extn
January 16, 2023
Title: BEXMAB study update
January 16, 2023
Faron's Financial Calendar for 2023
December 23, 2022
BEXMAB Study Update
December 5, 2022
Faron Appoints Maija Hollmén PhD as CSO
December 1, 2022
Amendment Terms and Conditions with IPF Partners
November 18, 2022
Faron Announces Poster Presentation at SITC
November 2, 2022
Faron Announces Melanoma Cohort Data from MATINS
October 18, 2022
Proposed Issue and Placing of Shares
October 13, 2022
Top-Line Data on Bexmarilimab Dose Variation
September 20, 2022
Faron to Host Bexmarilimab Update Webcast
September 14, 2022
Traumakine Data Presented at MHSR Symposium
September 13, 2022
Faron to Present at Upcoming Conferences
September 7, 2022
Faron Reports 2022 Half-Year Financial Results
August 25, 2022
Registration of New Shares
June 28, 2022
Faron notice of EGM
June 16, 2022
Faron Announces Top-Line 12-Month Survival Results
June 15, 2022
First Patient Dosed in Ph I/II BEXMAB Combo Study
June 8, 2022
Presentation of Biomarker Analysis at ASCO
May 30, 2022
FDA and FIMEA approve BEXMAB study to begin
May 16, 2022
Ex Vivo Data Presented at EHA2022 Congress
May 12, 2022
Mol Cancer Ther Publishes Bexmarilimab Research
May 9, 2022
Faron Presents Melanoma Data at EADO
April 21, 2022